Liposomes in Biology and Medicine

Drug delivery systems (DDS) have become important tools for the specific delivery of a large number of drug molecules. Since their discovery in the 1960s liposomes were recognized as models to study biological membranes and as versatile DDS of both hydrophilic and lipophilic molecules. Liposomes--nanosized unilamellar phospholipid bilayer vesicles--undoubtedly represent the most extensively studied and advanced drug delivery vehicles. After a long period of research and development efforts, liposome-formulated drugs have now entered the clinics to treat cancer and systemic or local fungal infections, mainly because they are biologically inert and biocompatible and practically do not cause unwanted toxic or antigenic reactions. A novel, up-coming and promising therapy approach for the treatment of solid tumors is the depletion of macrophages, particularly tumor associated macrophages with bisphosphonate-containing liposomes. In the advent of the use of genetic material as therapeutic molecules the development of delivery systems to target such novel drug molecules to cells or to target organs becomes increasingly important. Liposomes, in particular lipid-DNA complexes termed lipoplexes, compete successfully with viral gene transfection systems in this field of application. Future DDS will mostly be based on protein, peptide and DNA therapeutics and their next generation analogs and derivatives. Due to their versatility and vast body of known properties liposome-based formulations will continue to occupy a leading role among the large selection of emerging DDS

The use of the Fourier Transform Infrared spectroscopy to determine adulterants in raw milk

The objective of this study was to develop calibrations to determine the concentration of some milk adulterants by using the automated methodology of Fourier Transform Infrared (FTIR). For construction of calibrations, samples were collected from 100 farms in the states of São Paulo and Minas Gerais. Samples were tainted with three different adulterants commonly used in the adulteration of raw milk: sodium bicarbonate (SB), sodium citrate (SC) and cheese whey (W). Each adulterant was used at three different concentrations (SB: 0.05, 0.10 and 0.25%; SC: 0.025, 0.050 and 0.075% and W: 5, 10 and 20%). For validation, 60 samples were collected in other farms, which were not considered at the development stage of calibration. Adulterants were added at the following concentrations: 0.03, 0.06, 0.10 and 0.12% for SB; 0.02, 0.04, 0.06 and 0.08% for SC and 5, 10 and 20% for W. Performance of each calibration was evaluated in terms of accuracy (Se), detection limit (DL) and determination coefficient (R²). All calibrations presented R² higher than 0.91 with DL of 0.015%; 0.017% and 3.9% for SB, SC and W, respectively. Accuracy was 0.005%, 0.009% and 2.26% for SB, SC and W, respectively. Results show that the FTIR methodology can be used for determining the concentration of sodium bicarbonate, sodium citrate and whey in raw milk. Associated with automated equipment, it is a viable option for monitoring these adulterants, having low operational costs and high analytical performance as additional features

Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma

Melanoma heritability is among the highest for cancer and single nucleotide polymorphisms (SNPs) contribute to it. To date, only SNPs that reached statistical significance in genome-wide association studies or few candidate SNPs have been included in melanoma risk prediction models. We compared four approaches for building polygenic risk scores (PRS) using 12 874 melanoma cases and 23 203 controls from Melanoma Meta-Analysis Consortium as a training set, and newly genotyped 3102 cases and 2301 controls from the MelaNostrum consortium for validation. We estimated adjusted odds ratios (ORs) for melanoma risk using traditional melanoma risk factors and the PRS with the largest area under the receiver operator characteristics curve (AUC). We estimated absolute risks combining the PRS and other risk factors, with age- and sex-specific melanoma incidence and competing mortality rates from Italy as an example. The best PRS, including 204 SNPs (AUC = 64.4%; 95% confidence interval (CI) = 63-65.8%), developed using winner's curse estimate corrections, had a per-quintile OR = 1.35 (95% CI = 1.30-1.41), corresponding to a 3.33-fold increase comparing the 5th to the 1st PRS quintile. The AUC improvement by adding the PRS was up to 7%, depending on adjusted factors and country. The 20-year absolute risk estimates based on the PRS, nevus count and pigmentation characteristics for a 60-year-old Italian man ranged from 0.5 to 11.8% (relative risk = 26.34), indicating good separation. © 2018 Lippincott Williams and Wilkins.All Rights Reserved

Melanoma prone families with CDK4 germline mutation: Phenotypic profile and associations with MC1R variants

CDKN2A and CDK4 are high risk susceptibility genes for cutaneous malignant melanoma. Melanoma families with CDKN2A germline mutations have been extensively characterised, whereas CDK4 families are rare and lack a systematic investigation of their phenotype. All known families with CDK4 germline mutations (n=17) were recruited for the study by contacting the authors of published papers or by requests via the Melanoma Genetics Consortium (GenoMEL). Phenotypic data related to primary melanoma and pigmentation characteristics were collected. The CDK4 exon 2 and the complete coding region of the MC1R gene were sequenced. Eleven families carried the CDK4 R24H mutation whereas six families had the R24C mutation. The total number of subjects with verified melanoma was 103, with a median age at first melanoma diagnosis of 39 years. Forty-three (41.7%) subjects had developed multiple primary melanomas (MPM). A CDK4 mutation was found in 89 (including 62 melanoma cases) of 209 tested subjects. CDK4 positive family members (both melanoma cases and unaffected subjects) were more likely to have clinically atypical nevi than CDK4 negative family members ( p<0.001). MPM subjects had a higher frequency of MC1R red hair colour variants compared with subjects with one tumour (p=0.010). Our study shows that families with CDK4 germline mutations cannot be distinguished phenotypically from CDKN2A melanoma families, which are characterised by early onset of disease, increased occurrence of clinically atypical nevi, and development of MPM. In a clinical setting, the CDK4 gene should therefore always be examined when a melanoma family tests negative for CDKN2A mutation

Search For Poliovirus Carriers Among People With Primary Immune Deficiency Diseases In The United States, Mexico, Brazil, And The United Kingdom

Objective: To estimate the rate of long-term poliovirus excretors in people known to have B-cell immune deficiency disorders. Methods: An active search for chronic excretors was conducted among 306 persons known to have immunoglobulin G (IgG) deficiency in the United States, Mexico, Brazil, and the United Kingdom, and 40 people with IgA deficiency in the United States. Written informed consent or assent was obtained from the participants or their legal guardians, and the studies were formally approved. Stool samples were collected from participants and cultured for polioviruses. Calculation of the confidence interval for the proportion of participants with persistent poliovirus excretion was based on the binomial distribution. Findings: No individuals with long-term excretion of polioviruses were identified. Most participants had received oral poliovirus vaccine (OPV) and almost all had been exposed to household contacts who had received OPV. Polioviruses of recent vaccine origin were transiently found in four individuals in Mexico and Brazil, where OPV is recommended for all children. Conclusion: Although chronic poliovirus excretion can occur in immunodeficient persons, it appears to be rare.82138Benyesh-Melnick, M., Melnick, J.L., Rawls, W.E., Wimberly, I., Oro, J.B., Ben-Porath, E., Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter (1967) American Journal of Epidemiology, 86, pp. 112-136Melnick, J.L., Benyesh-Melnick, M., Brennan, J.C., Studies on live poliovirus vaccines. Its neurotropic activity in monkeys and its increased neurovirulence after multiplication in vaccinated children (1959) JAMA, 171, pp. 1165-1172Gelfand, H.M., Potash, L., LeBlanc, D.R., Fox, J.P., Revised preliminary report on the Louisiana observations of the natural spread within families of living vaccine strains of poliovirus (1959) Live Poliovirus Vaccines: Papers Presented and Discussions Held at the First International Conference on Live Poliovirus Vaccines, , Special Publication No. 44. Washington (DC): Pan American Sanitary BureauFox, J.P., Gelfand, H.M., LeBlanc, D.R., Potash, L., Clemmer, D.I., LaPenta, D., The spread of vaccine strains of poliovirus in the household and in the community in southern Louisiana (1961) International Poliomyelitis Congress, Ed. Poliomyelitis: Papers and Discussions Presented at the Fifth International Poliomyelitis Conference, pp. 368-383. , Philadelphia: LippincottSutter, R.W., Cochi, S.L., Melnick, J.L., Live attenuated poliovirus vaccines (1999) Vaccines, 3rd Ed., pp. 364-408. , Plotkin SA, Orenstein WA, editors. Philadelphia: WB SaundersModlin, J.F., Coxsackieviruses, echoviruses, and newer enteroviruses (2000) Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th Ed., pp. 1904-1919. , Mandell GL, Bennett JE, Dolin R, editors. Philadelphia (PA): Churchill-LivingstoneWood, D.J., Sutter, R.W., Dowdle, W.R., Stopping poliovirus vaccination after eradication: Issues and challenges (2000) Bulletin of the World Health Organization, 78, pp. 347-357Kew, O.M., Sutter, R.W., Nottay, B.K., McDonough, M.J., Prevots, D.R., Quick, L., Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient (1998) Journal of Clinical Microbiology, 36, pp. 2893-2899Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis (2003) Journal of General Virology, 84, pp. 1215-1221John, T.J., Walker, D.H., Enterovirus infections, including poliomyelitis (1999) Tropical Infectious Diseases, Principles, Pathogens, and Practice, pp. 1123-1132. , Guerrant RL, Walker DH, Weller PF, editors. Philadelphia: Churchill LivingstoneMinor, P., Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies (2001) Developmental Biology, 105, pp. 75-80Minor, P.D., Ferguson, J.A., Icenogle, J.P., Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee (1986) Journal of General Virology, 67, pp. 693-706Dunn, G., Begg, N.T., Cammack, N., Minor, P.D., Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources (1990) Journal of Medical Virology, 32, pp. 92-95Sutter, R.W., Tangermann, R.H., Aylward, R.B., Cochi, S.L., Poliomyelitis eradication: Progress, challenges for the end game, and preparation for the post-eradication era (2001) Infectious Disease Clinics of North America, 15, pp. 41-64Conley, M.E., Notarangelo, L.D., Etzioni, A., Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and eSID (European Society for Immunodeficiencies) (1999) Clinical Immunology, 93, pp. 190-197(1997) Manual of the Virological Investigation of Poliomyelitis, , Geneva: World Health Organization. WHO document WHO/EPI/GEN/9701Liu, H.M., Zheng, D.P., Zhang, L.B., Oberste, M.S., Pallansch, M.A., Kew, O.M., Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China (2000) Journal of Virology, 74, pp. 11153-11161Savilahti, E., Klemola, T., Carlsson, B., Mellander, L., Stenvik, M., Hovi, T., Inadequacy of mucosal IgM antibodies in selective IgA deficiency excretion of attenuated polio viruses is prolonged (1988) Journal of Clinical Immunology, 8, pp. 89-94Triki, H., Barbouche, M.R., Bahri, O., Bejaoui, M., Dellagi, K., Community-acquired poliovirus infection in children with primary immunodeficiency in Tunisia (2003) Journal of Clinical Microbiology, 41, pp. 1203-1211Hammon, W.D., Coriell, L.L., Wehrle, P.F., Stokes, J., Evaluation of Red Cross gammaglobulin as a prophylactic agent for poliomyelitis. 4. Final report of results based on clinical diagnosis (1953) JAMA, 151, pp. 1272-1285Halliday, E., Winkelstein, J., Webster, A.D., Enteroviral infections in primary immunodeficiency (PID): A survey of morbidity and mortality (2003) The Journal of Infection, 46, pp. 1-8Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis (2003) Journal of General Virology, 84, pp. 1215-1221Cunningham-Rundles, C., Bodian, C., Common variable immunodeficiency: Clinical and immunological features of 248 patients (1999) Clinical Immunology, 92, pp. 34-48Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus (2002) Science, 296, pp. 356-359Halsey, N.A., Commentary: Poliomyelitis and unnecessary injections (2003) International Journal of Epidemiology, 32, pp. 278-279Halsey, N.A., Combination vaccines: Defining and addressing current safety concerns (2001) Clinical Infectious Diseases, 33 (SUPPL. 4), pp. S312-S31